Prelude Therapeutics Incorporated
NASDAQ:PRLDBiotechnology
-$0.14 today
- Market cap
- $191.00M
- Beta
- 1.01
- P/E (TTM)
- -4.5
- EPS (TTM)
- -$0.94
Volume 0.23M
Average 0.38M
PRLD Change in Working Capital
Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.
Prelude Therapeutics IncorporatedNASDAQ: PRLD
Change in Working Capital · Q1 FY2026 · quarter ended Mar 2026
Change in working capital grows, but more slowly than its trailing trend
Q1 FY2026 change in working capital of $13.69M (cash outflow) rose 99.1% year over year, behind the +725.2% change in trailing-twelve-month change in working capital. Over 3 fiscal years it compounded at +212.4% a year.
Context
- Change in working capital amounted to 234.0% of revenue in FY2025, up 173.8 pp from a year earlier.
- Change in working capital increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +99.1% toward the trailing-twelve-month pace of +725.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Change in Working Capital history
USD · from the cash flow
- Latest · FY2025
- 28.41M USD
- Year-over-year change
- +573.8%
- 4-year CAGR
- +67.3%
| Period | Period end | Change in Working Capital | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 28.41M | +573.8% |
| FY2024 | 2024-12-31 | 4.22M | +140.2% |
| FY2023 | 2023-12-31 | (10.48M) | -1224.4% |
| FY2022 | 2022-12-31 | 932K | -74.3% |
| FY2021 | 2021-12-31 | 3.63M | — |
Change in Working Capital vs competitors
How PRLD compares with its peers on the latest reported figures
- Peers report in different currencies, so change in working capital is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +725.2% is the 2nd highest of 11, against a peer median of +68.0%.
- Change in working capital amounts to 129.2% of revenue for PRLD, versus a peer median of 80.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $34.76M USD | +146.8% | +80.5% | 50.2% | |
| LTM Mar 2026 | $31.04M USD | -3.9% | — | 110.0% | |
| LTM Mar 2026 | $21.6M USD | +725.2% | +212.4% | 129.2% | |
| LTM Mar 2026 | $13.05M USD | +2413.5% | +184.4% | 39.9% | |
| FY2025 | €6.42M EUR | +282.2% | +4.0% | 143.1% | |
| LTM Mar 2026 | $3.94M USD | -31.6% | -51.0% | 35.2% | |
| LTM Mar 2026 | $3.6M USD | -53.4% | +42.5% | 1601.8% | |
EPRXEupraxia Pharmaceuticals Inc. | LTM Mar 2026 | $2.27M USD | +139.8% | — | — |
| LTM Mar 2026 | $2.15M USD | -59.7% | -24.4% | 15.5% | |
| LTM Mar 2026 | $1.66M USD | -293.7% | +30.6% | — | |
| LTM Mar 2026 | $1.57M USD | +169.6% | — | 2652.5% | |
| Peer median (excluding PRLD) | — | +68.0% | +30.6% | 80.1% | |
Competitors are the stored peer set for PRLD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (111.69M) | (115.44M) | (121.83M) | (127.17M) | (99.5M) |
| Depreciation & Amortization | 915K | 1.32M | 1.17M | 1.77M | 1.34M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 20.93M | 25.14M | 25.62M | 21.35M | 11.91M |
| Change in Working Capital | 3.63M | 932K | (10.48M) | 4.22M | 28.41M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 3.9M | (347K) | (2.27M) | 3.31M | (3.92M) |
| Other Working Capital | (278K) | 1.28M | (8.21M) | 911K | 32.33M |
| Other Non-Cash Items | 2.69M | 4.31M | (1.54M) | (3.05M) | 1.53M |
| Operating Cash Flow | (83.53M) | (83.73M) | (107.06M) | (102.89M) | (56.3M) |
| Capital Expenditures | (2.32M) | (3.02M) | (3.51M) | (764K) | (67K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (261.48M) | (119.22M) | (221.63M) | (52.69M) | (100.87M) |
| Sales of Investments | 0 | 203.93M | 190.5M | 143.65M | 154.39M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (263.8M) | 81.69M | (34.65M) | 90.19M | 53.46M |
| Debt Repayment | 0 | 0 | 0 | (395K) | (208K) |
| Common Stock Issued | 161.42M | 815K | 135.73M | 329K | 25.04M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 3.47M | 0 | 664K | (54K) | (17K) |
| Financing Cash Flow | 164.9M | 815K | 136.4M | (120K) | 24.82M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (182.44M) | (1.22M) | (5.31M) | (12.82M) | 21.97M |
| Free Cash Flow | (85.85M) | (86.75M) | (110.58M) | (103.65M) | (56.37M) |
Prelude Therapeutics Incorporated
NASDAQ:PRLD
Intrinsic Alpha fair value
Locked
Current Price
$3.30
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.